{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:56:44Z","timestamp":1791597404362,"version":"4.3.4"},"reference-count":37,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:00:00Z","timestamp":1719619200000},"content-version":"unspecified","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Vidi-grant from the Dutch Research Council","award":["015.021.021"],"award-info":[{"award-number":["015.021.021"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,6,9]]},"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Treatment with the immune checkpoint inhibitor anti-programmed cell death protein-1 (PD-1) often causes immune-related adverse events (irAEs). Since irAEs resemble autoimmune diseases, autoantibodies might play a role and could potentially be used to identify patients at risk. Therefore, we investigated the association between autoantibody-positivity and toxicity as well as clinical response in patients with melanoma treated with anti-PD-1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This two-center, retrospective study included 143 patients with melanoma treated with anti-PD-1. Toxicities grade \u22652\u2009and recurrences\/responses were captured until 6\u2009months after treatment initiation. Autoantibody measurements were performed at baseline and 3\u2009months after treatment initiation, including IgM-rheumatoid factor (RF), antinuclear antibodies (ANA), extractable nuclear antigen, anti-cyclic citrullinated peptide antibodies (anti-CCP2) and anti-thyroid antibodies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>169 irAEs were experienced by 86\/143 patients (137 grades 1\u20132, 32 grades 3\u20134), the most common being thyroiditis (n=25), dermatitis (n=24), and sicca problems (n=19). Patients with autoantibodies at baseline experienced more irAEs (p=0.001), predominantly associated with anti-thyroid antibodies and thyroid dysfunction. No association was observed between any irAE and anti-CCP2, RF or ANA. In women, baseline and on-treatment anti-thyroid antibody-positivity as well as seroconversion during treatment was associated with thyroid dysfunction. In men, this association was only observed on-treatment. The presence of autoantibodies was not associated with melanoma recurrence (p=0.776) or response (p=0.597).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The presence of autoantibodies prior to anti-PD-1 therapy is associated with irAEs in patients with melanoma. Both baseline positivity and seroconversion of anti-thyroid antibodies were strongly associated with thyroid dysfunction. This association was stronger in women, with all women who were baseline positive developing thyroid dysfunction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2024-009215","type":"journal-article","created":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T11:05:14Z","timestamp":1719745514000},"page":"e009215","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":22,"title":["Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6478-7821","authenticated-orcid":false,"given":"Jessica S W","family":"Borgers","sequence":"first","affiliation":[{"name":"Medical Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tineke J","family":"van Wesemael","sequence":"additional","affiliation":[{"name":"Rheumatology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyra A","family":"Gelderman","sequence":"additional","affiliation":[{"name":"Sanquin Diagnostic Services, Amsterdam, Noord-Holland, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Rispens","sequence":"additional","affiliation":[{"name":"Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam, Noord-Holland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4449-8707","authenticated-orcid":false,"given":"Els M E","family":"Verdegaal","sequence":"additional","affiliation":[{"name":"Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk J A R","family":"Moes","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina M","family":"Korse","sequence":"additional","affiliation":[{"name":"Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4814-6426","authenticated-orcid":false,"given":"Ellen","family":"Kapiteijn","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marij J P","family":"Welters","sequence":"additional","affiliation":[{"name":"Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-0354","authenticated-orcid":false,"given":"Sjoerd H","family":"van der Burg","sequence":"additional","affiliation":[{"name":"Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winan J","family":"van Houdt","sequence":"additional","affiliation":[{"name":"Surgical Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes V","family":"van Thienen","sequence":"additional","affiliation":[{"name":"Medical Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5884-7704","authenticated-orcid":false,"given":"John B A G","family":"Haanen","sequence":"additional","affiliation":[{"name":"Medical Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands"},{"name":"Department of Medical Oncology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"van der Woude","sequence":"additional","affiliation":[{"name":"Rheumatology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,6,30]]},"reference":[{"key":"2025100308155073000_12.6.e009215.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01206-X"},{"key":"2025100308155073000_12.6.e009215.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0"},{"key":"2025100308155073000_12.6.e009215.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.1389"},{"key":"2025100308155073000_12.6.e009215.4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225"},{"key":"2025100308155073000_12.6.e009215.5","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.autrev.2016.01.017","article-title":"Autoantibody production in cancer\u2014the humoral immune response toward Autologous antigens in cancer patients","volume":"15","author":"Zaenker","year":"2016","journal-title":"Autoimmun Rev"},{"key":"2025100308155073000_12.6.e009215.6","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxs098"},{"key":"2025100308155073000_12.6.e009215.7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96798"},{"key":"2025100308155073000_12.6.e009215.8","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0245"},{"key":"2025100308155073000_12.6.e009215.9","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-018-1452-4","article-title":"Baseline antibody profiles predict toxicity in Melanoma patients treated with immune Checkpoint inhibitors","volume":"16","author":"Gowen","year":"2018","journal-title":"J Transl Med"},{"key":"2025100308155073000_12.6.e009215.10","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamaoncol.2018.5860","article-title":"Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer","volume":"5","author":"Toi","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100308155073000_12.6.e009215.11","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0523-2","article-title":"Antibodies as biomarker candidates for response and survival to Checkpoint inhibitors in Melanoma patients","volume":"7","author":"F\u00e4ssler","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025100308155073000_12.6.e009215.12","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13800"},{"key":"2025100308155073000_12.6.e009215.13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1908079116"},{"key":"2025100308155073000_12.6.e009215.14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0404"},{"key":"2025100308155073000_12.6.e009215.15","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001777"},{"key":"2025100308155073000_12.6.e009215.16","doi-asserted-by":"crossref","first-page":"e3704","DOI":"10.1210\/clinem\/dgab263","article-title":"Thyroid immune-related adverse events following immune Checkpoint inhibitor treatment","volume":"106","author":"Muir","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2025100308155073000_12.6.e009215.17","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2018.1489246"},{"key":"2025100308155073000_12.6.e009215.18","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000025318","article-title":"Prognostic value of lactate dehydrogenase for Melanoma patients receiving anti-PD-1\/PD-L1 therapy: A meta-analysis","volume":"100","author":"Xu","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"2025100308155073000_12.6.e009215.19","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0386"},{"key":"2025100308155073000_12.6.e009215.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01211-7"},{"key":"2025100308155073000_12.6.e009215.21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3073"},{"key":"2025100308155073000_12.6.e009215.22","first-page":"1","article-title":"Thyroid peroxidase Autoantibodies in euthyroid subjects. best Pract Res Clin Endocrinol Metab","volume":"19","author":"Prummel","year":"2005","journal-title":"Mar"},{"key":"2025100308155073000_12.6.e009215.23","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3803\/EnM.2020.906","article-title":"Characteristics of immune-related thyroid adverse events in patients treated with PD-1\/PD-L1 inhibitors","volume":"36","author":"Yoon","year":"2021","journal-title":"Endocrinol Metab (Seoul)"},{"key":"2025100308155073000_12.6.e009215.24","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw640"},{"key":"2025100308155073000_12.6.e009215.25","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s40618-020-01480-6","article-title":"Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with Immunotherapy","volume":"44","author":"Brilli","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"2025100308155073000_12.6.e009215.26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb7495","article-title":"Cd4(+) T cells are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized mice","volume":"13","author":"Yasuda","year":"2021","journal-title":"Sci Transl Med"},{"key":"2025100308155073000_12.6.e009215.27","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2409"},{"key":"2025100308155073000_12.6.e009215.28","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004008","article-title":"Lower baseline autoantibody levels are associated with immune-related adverse events from immune Checkpoint inhibition","volume":"10","author":"Ghosh","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100308155073000_12.6.e009215.29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.lungcan.2019.01.014","article-title":"Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for Antinuclear antibodies","volume":"130","author":"Yoneshima","year":"2019","journal-title":"Lung Cancer"},{"key":"2025100308155073000_12.6.e009215.30","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s12094-019-02214-8","article-title":"Safety and efficacy of PD-1\/PD-L1 blockade in patients with preexisting Antinuclear antibodies","volume":"22","author":"Sakakida","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"2025100308155073000_12.6.e009215.31","first-page":"81","article-title":"Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and Autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by Nivolumab","volume":"11","author":"Giannicola","year":"2019","journal-title":"Mol Clin Oncol"},{"key":"2025100308155073000_12.6.e009215.32","first-page":"2034","article-title":"Rheumatoid factors: what do they tell us","volume":"29","author":"Newkirk","year":"2002","journal-title":"J Rheumatol"},{"key":"2025100308155073000_12.6.e009215.33","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400909"},{"key":"2025100308155073000_12.6.e009215.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2017.07.003"},{"key":"2025100308155073000_12.6.e009215.35","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune Checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025100308155073000_12.6.e009215.36","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/jamaoncol.2016.2238","article-title":"Prevalence of autoimmune disease among patients with lung cancer: implications for Immunotherapy treatment options","volume":"2","author":"Khan","year":"2016","journal-title":"JAMA Oncol"},{"key":"2025100308155073000_12.6.e009215.37","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced Melanoma and preexisting autoimmune disorders or major toxicity with Ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Annals of Oncology"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-009215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T15:16:00Z","timestamp":1759504560000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-009215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,30]]},"published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1136\/jitc-2024-009215"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-009215","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]}}}